SSCI, part of AMRI’s Global Analytical Services, will expand its nuclear magnetic resonance (NMR) spectroscopy capabilities with the addition of the Bruker AVANCE NEO 600 MHz NMR Spectrometer.
“NMR is a core technology of our global analytical and solid state chemistry service offering. Our investment in this state-of-the-art spectrometer reflects our continued commitment to provide our world-class NMR scientists with the tools necessary to obtain crucial chemical information for the clients we serve,” said Pamela Smith, Ph.D., vice president, global analytical services.
The Bruker AVANCE NEO 600 MHz NMR will provide SSCI with enhanced productivity for delivering high quality NMR data with increased sensitivity utilizing a cryoprobe. Having the 600 MHz NMR spectrometer will c omplement the existing 400 MHz NMR spectrometer already in cGMP service at SSCI. This higher field instrument will expand the tools that SSCI’s scientists have to support rigorous method development and validation and complex structure elucidation for small and large molecule applications, including peptides, proteins (such as monoclonal antibodies and antibody-drug conjugates), modified or unmodified ribonucleic acids (RNA), and deoxyribonucleic acids (DNA). This capability will also allow SSCI to support the FDA requirements for biosimilarity testing and USP (e.g., heparin) testing requiring higher field NMR.
The new 600 MHz NMR spectrometer, which will be operational in late 2018, provides direct access to high-quality data as a stand-alone service offering and will further enhance the valuable information that AMRI delivers from other chemistry services including polymorph, salt and cocrystal screens. By consulting with AMRI now, clients can factor the expanded capability into their project timelines to ensure it will be ready for their programs.
According to Patrick Tishmack, Ph.D., director of analytical development at SSCI, this addition will bring significant value to AMRI’s clients. “With two NMR spectrometers configured for testing of liquid and solid samples concurrently and under cGMP, coupled with our industry-leading expertise in solid-state chemistry, will result in data and corresponding expert scientific interpretation at a standard that is unmatched in the contract solid-state and analytical services industry,” Dr. Tishmack said.